iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021

Rhea-AI Summary

iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical firm, will have its CEO Michel Detheux, PhD, participate in a panel at the William Blair Biotech Focus Conference 2021 on July 14, 2021, at 2:10 p.m. ET. The discussion will revolve around developing therapies for new immuno-oncology targets. A live webcast of the event will be available on the company’s website, with an archived replay accessible for 30 days post-event. iTeos focuses on innovative immuno-oncology therapeutics, with clinical programs such as EOS-448 and inupadenant showing promising early results.

CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 08, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming William Blair Biotech Focus Conference 2021 titled: “Developing Therapies for the Next IO Targets” on Wednesday, July 14, 2021 at 2:10 p.m. ET.

A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

For further information, please contact:

Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com

FAQ

What is the date and time of iTeos Therapeutics' participation in the William Blair Biotech Focus Conference 2021?

iTeos Therapeutics will participate in the conference on July 14, 2021, at 2:10 p.m. ET.

Where can I watch the presentation from iTeos Therapeutics' CEO Michel Detheux?

The presentation can be viewed live on the Investors section of iTeos Therapeutics' website.

What are the key clinical programs being developed by iTeos Therapeutics?

iTeos Therapeutics is developing EOS-448 and inupadenant, which are in clinical trials for immuno-oncology.

What is the focus of the panel discussion that iTeos Therapeutics will participate in?

The panel discussion will focus on developing therapies for the next immuno-oncology targets.

How long will the archived webcast of iTeos Therapeutics' presentation be available?

The archived webcast will be available for approximately 30 days following the presentation.